Narasimha Rao: FDA recommendations on immunogenicity risk assessment for synthetic peptide drugs
57:15
Evaluation of Elemental Impurities in Drugs and Drug Products ICH Q3D(R2)
25:08
Webinar: Immunogenicity Risk Assessment for Innate Immune Response Modulating Impurities (IIRMI)
27:04
Charlotte Thompson: Ankyrons: The future of target-binding reagents beyond antibodies
47:40
Panel Discussion on peptides characterization and Impurities
36:31
New Dogs/Old Tricks: Methods for Assessing the Immunogenicity of Peptide Drugs and Their Impurities
25:57
(Mastering JMP) Analyzing the Potency and Stability of Bioassays
24:07
Koen Venken: Modulatory roles of Tregs in gut vs joint inflammation in TNF-driven spondyloarthritis
22:34